Please assess the completion status of the following clinical trial:

Trial Title: Modifiers of Tenofovir in the Female Genital Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, or transgender female with a cervix, aged 18-35 years old~* HIV-positive~* Stable on antiretroviral regimen containing TDF for at least 2 weeks at time of enrollment.~* Virally suppressed (HIV-RNA copies \<50 copies/mL) for at least 6 months at time of enrollment.~* Willing to refrain from vaginal intercourse and use of vaginal devices such as douches and sex toys within 72 hours of the biopsy visit.~* Willing and able to give signed informed consent.~Exclusion Criteria:~* Currently pregnant or previous pregnancy within 3 months of enrollment~* Currently breast feeding~* Symptomatic vaginal infection within 2 weeks prior to enrollment~* Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynecologic surgery within 90 days prior to enrollment~* History of vulvar/vaginal/ cervical dysplasia, neoplasia or cancer, atypical squamous cells of undetermined significance, condyloma, or human papilloma virus (HPV) in the past year~* Use of oral and/or vaginal preparations of antibiotic or antifungal medications within 30 days prior to the enrollment visit

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Depo-Provera (Type: None): None
- Non-hormonal contraception (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).